B. Riley raised the firm’s price target on Cognition Therapeutics (CGTX) to $2 from $1.50 and keeps a Buy rating on the shares. The firm updated its zervimesine model estimates to reflect specialty drug pricing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDC
- Cognition Therapeutics Shows Promising Phase 2 Study Results
- B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data
- Cognition Therapeutics upgraded to Buy from Neutral at B. Riley
- Cognition Therapeutics price target raised to $6 from $5 at H.C. Wainwright